The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo’s branded Ozempic and Wegovy on its telehealth platform. More: Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims’
read moreWith a new FDA nod in hand for Sotyktu as a treatment for adults with active psoriatic arthritis, Bristol Myers Squibb can reach more patients with the oral TYK2 inhibitor. More: Sotyktu take 2: BMS' first-in-class pill gains FDA nod
read more
Phase 3 Mascot study reaches key milestone for potential first-in-class therapy More: Lundbeck completes patient randomisation early in global MSA trial Source: News
read more
EC decision introduces first systemic option for adults with advanced SCAC More: Incyte treatment for advanced anal cancer approved in Europe Source: News
read moreUnder the deal with Lone Star Funds, Lonza maintains a 40% stake in its capsules and health ingredients business while receiving 1.7 billion Swiss francs ($2.2 billion) upfront. More: Lonza hands off capsule business to investment firm Lone Star in
read moreSen. Ron Wyden of Oregon is going straight to drugmakers in search of details on their “most favored nation” pricing deals with Donald Trump. More: Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid
read more© 1994 - 2026 B.M. Pharmaceuticals